×
About 1,920 results

ALLMedicine™ Folliculitis Center

Research & Reviews  539 results

More New Therapeutics for Psoriasis
https://www.mdedge.com/dermatology/article/260942/psoriasis/more-new-therapeutics-psoriasis
Christina Kontzias, BA, Steven R. Feldman, MD, PhD

Jan 31st, 2023 - New treatments for psoriasis constitute an embarrassment of riches compared to any other area of dermatology. Despite the many advances over the last 25 years, additional topical and systemic treatments have recently become available.

Folliculitis decalvans has a heterogeneous microbiological signature and impaired immun...
https://doi.org/10.1159/000529301
Dermatology (Basel, Switzerland); Moreno-Arrones ÓM, García-Hoz C et. al.

Jan 31st, 2023 - Folliculitis decalvans (FD) is a rare primary neutrophilic scarring alopecia whose etiology has not been completely elucidated yet. To determine if the follicular microbiota residing in FD-affected hair follicles had a distinct microbiological sig...

EGFR inhibitor-induced folliculitis decalvans: a case series and management guidelines.
https://doi.org/10.1097/CAD.0000000000001494
Anti-cancer Drugs; Nowaczyk J, Fret K et. al.

Jan 29th, 2023 - Epidermal growth factor receptor (EGFR) is one of therapeutic targets in oncology for solid tumors originating from epithelial tissue, such as non-small-cell lung carcinoma (NSCLC) and breast cancer. EGFR inhibitors used in cancer treatment may ca...

Comment on 'Eosinophilic pustular folliculitis developing at the site of COVID-19 vacci...
https://doi.org/10.1093/ced/llac006
Clinical and Experimental Dermatology; Martora F, Battista T et. al.

Jan 21st, 2023 - Comment on 'Eosinophilic pustular folliculitis developing at the site of COVID-19 vaccination'.|2023|Martora F,Battista T,Fabbrocini G,Potestio L,|prevention & control,adverse effects,etiology,

Tumor necrosis factor-alpha inhibitors and acne fulminans: Friend or foe?
https://doi.org/10.1111/pde.15226
Pediatric Dermatology; Barry KK, Neale HD et. al.

Dec 28th, 2022 - Acne fulminans (AF) is an uncommon variant of inflammatory acne with abrupt eruption of painful nodules, pustules, and hemorrhagic ulcerations, often associated with systemic symptoms. Paradoxical adverse reactions to tumor necrosis (TNF)-alpha in...

see more →

Drugs  49 results see all →

Clinicaltrials.gov  17 results

Duobrii Treatment of Acne Keloidalis Nuchae (AKN)
https://clinicaltrials.gov/ct2/show/NCT05608499

Nov 8th, 2022 - Acne keloidalis nuchae (AKN) is one of the chronic forms of scarring folliculitis, affecting predominantly the occipital scalp, seen mostly in men of African descent. Duobrii has the advantage of being the only high potency topical steroid-retinoi...

Effect of Cold Atmospheric Plasma on Malassezia Folliculitis
https://clinicaltrials.gov/ct2/show/NCT04886323

Sep 22nd, 2022 - Malassezia folliculitis is a common disease of young and middle-aged people. It is an inflammatory disease caused by Malassezia infection. Generally, Topical or systemic use of antifungal drugs are the first choice for treatment but sometimes are ...

Evaluation of Safety and Performance of Ialuxid Gel in Treatment of Acne Vulgaris, Impetigo and Folliculitis
https://clinicaltrials.gov/ct2/show/NCT05345093

May 2nd, 2022 - Ialuxid® Gel is a non-antibiotic treatment in gel indicated for use in a variety of skin conditions, and also in case of infection. Its principal ingredient is Ialuvance™ Complex, a proprietary association of hydrogen peroxide, hyaluronic acid, an...

Effect of Various Treatment Modalities on Dendritic Vial Ulcer
https://clinicaltrials.gov/ct2/show/NCT05313828

Apr 6th, 2022 - Eye infection is a prevalent problem in primary care and remains a crucial healthcare concern. According to the American Academy of Ophthalmology (AAO), herpes simplex virus (HSV) keratitis (HSK) is the leading cause of infectious blindness worldw...

Skin bioMARkers for Atopic Eczema Therapy Evaluation
https://clinicaltrials.gov/ct2/show/NCT04194814

Dec 14th, 2021 - The first-line drug treatment for mild-moderate AD are currently topical corticosteroids (TCS) with recognized efficacy. However, their prolonged or inappropriate use, can lead to local adverse effects. Side-effects of topical corticosteroids comp...

see more →

News  146 results

More New Therapeutics for Psoriasis
https://www.mdedge.com/dermatology/article/260942/psoriasis/more-new-therapeutics-psoriasis
Christina Kontzias, BA, Steven R. Feldman, MD, PhD

Jan 31st, 2023 - New treatments for psoriasis constitute an embarrassment of riches compared to any other area of dermatology. Despite the many advances over the last 25 years, additional topical and systemic treatments have recently become available.

HS treated in EDs not followed up in derm clinics, study finds
https://www.mdedge.com/dermatology/article/259857/medical-dermatology/hs-treated-eds-not-followed-derm-clinics-study-finds
Lorraine L. Janeczko, MPH

Dec 1st, 2022 - Many patients with hidradenitis suppurativa (HS) return to emergency departments – not to dermatology clinics – for their ongoing care, according to a study of a large national administrative data set. “Patients with HS presenting to the ED for th.

HS Treated in EDs Not Followed Up in Derm Clinics, Study Finds
https://www.medscape.com/viewarticle/984859

Dec 1st, 2022 - Many patients with hidradenitis suppurativa (HS) return to emergency departments – not to dermatology clinics – for their ongoing care, according to a study of a large national administrative data set. “Patients with HS presenting to the ED for th...

First TYK2 Inhibitor for Psoriasis Wins FDA Approval
https://www.medpagetoday.com/dermatology/psoriasis/100646

Sep 11th, 2022 - The FDA approved the first-in-class oral tyrosine kinase 2 (TYK2) inhibitor deucravacitinib (Sotyktu) for moderate-to-severe plaque psoriasis, Bristol Myers Squibb announced. The indication limits use to adults who are candidates for systemic ther...

FDA Approves First Systemic Treatment for Alopecia Areata
https://www.medpagetoday.com/dermatology/generaldermatology/99211

Jun 13th, 2022 - The FDA approved the Janus kinase (JAK) inhibitor baricitinib (Olumiant) as the first systemic treatment for alopecia areata. The approval pertains to adults with severe alopecia areata, which affects more than 300,000 people in the U.S. each year...

see more →

Patient Education  17 results see all →